Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Status:
RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML). The main questions it aims to answer are:
* What is the safety and tolerability profile of WBC100 in R/R AML patients?
* Can WBC100 effectively induce remission in R/R AML patients?
Participants will:
* Take WBC100 capsules orally once daily in 28-day treatment cycles;
* Undergo regular safety assessments, including adverse event monitoring and laboratory tests;
* Provide blood samples for pharmacokinetic (PK) analysis;
* Have their remission status and efficacy evaluated according to the ELN2022 criteria.